ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    Dr. Joe Mendez reviews the watch and wait vorasidenib patient profile in low-grade gliomas (Video 3/3)
    Sign up to watch this video

    Free access to all Sound Bites content

    Dr. Joe Mendez reviews the watch and wait vorasidenib patient profile in low-grade gliomas (Video 3/3)

    Published 1 month

    J

    Joe Mendez, MD

    Medical Professional

    INDIGO surveillance profile

    More in this series: INDIGO_2026
    Dr. Joe Mendez reviews vorasidenib for IDH mutant low-grade gliomas (Video 1/3)

    Dr. Joe Mendez reviews vorasidenib for IDH mutant low-grade gliomas (Video 1/3)

    INDIGO update

    Joe Mendez, MD
    CNS Malignancies
    Conference Updates
    +1 more
    Dr. Joe Mendez reviews the adjuvant vorasidenib patient profile in low-grade gliomas (Video 2/3)

    Dr. Joe Mendez reviews the adjuvant vorasidenib patient profile in low-grade gliomas (Video 2/3)

    INDIGO adjuvant profile

    Joe Mendez, MD
    CNS Malignancies
    Conference Updates
    +1 more
    Related Videos
    Dr. Gabriela Hobbs examines how ropeginterferon moves beyond disease control toward disease modification in the treatment of polycythemia vera. (Video 2/3)

    Dr. Gabriela Hobbs examines how ropeginterferon moves beyond disease control toward disease modification in the treatment of polycythemia vera. (Video 2/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein reviews the patient impact of treating AML at the first opportunity versus waiting for mutational testing (Video 2/3)

    Dr. Eytan Stein reviews the patient impact of treating AML at the first opportunity versus waiting for mutational testing (Video 2/3)

    Eytan Stein, MD
    Dr. Wade Iams discusses adverse event prophylaxis strategies for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 1/3)

    Dr. Wade Iams discusses adverse event prophylaxis strategies for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 1/3)

    Wade Iams, MD
    What makes ropeginterferon a modern interferon? Dr. Gabriela Hobbs explains. (Video 1/3)

    What makes ropeginterferon a modern interferon? Dr. Gabriela Hobbs explains. (Video 1/3)

    Gabriela Hobbs, MD
    Dr. Eytan Stein discusses durability of treatment in IC-ineligible AML (Video 1/3)

    Dr. Eytan Stein discusses durability of treatment in IC-ineligible AML (Video 1/3)

    Eytan Stein, MD
    Dr. Ghaith Abu-Zeinah discusses when to initiate treatment in essential thrombocythemia (Video 3/3)

    Dr. Ghaith Abu-Zeinah discusses when to initiate treatment in essential thrombocythemia (Video 3/3)

    Ghaith Abu-Zeinah, MD